首页> 外文OA文献 >PCN171 IDENTIFYING STRUCTURAL UNCERTAINTY IN ECONOMIC MODELS OF CANCER TREATMENTS: A CASE STUDY OF IRINOTECAN IN COLORECTAL CANCER (CRC)

【2h】

PCN171 IDENTIFYING STRUCTURAL UNCERTAINTY IN ECONOMIC MODELS OF CANCER TREATMENTS: A CASE STUDY OF IRINOTECAN IN COLORECTAL CANCER (CRC)

机译：PCN171识别癌症治疗经济模型中的结构不确定性：以大肠癌中伊立替康为例的研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Shabaruddin FH; Elliott RA; Valle JW; Saunders MP; Newman WG; Payne K;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104 - A randomized trial of the German AIO CRC study group [J] . MoosmannN., VonWeikersthalL.F., Vehling-KaiserU., Journal of Clinical Oncology . 2011,第8期

机译：西妥昔单抗联合卡培他滨和伊立替康与西妥昔单抗联合卡培他滨和奥沙利铂作为转移性结直肠癌患者的一线治疗：AIO KRK-0104-德国AIO CRC研究小组的一项随机试验
2. 238 Gemcitabine (GEM) as salvage treatment in patients (pts) with advanced colorectal cancer (CRC) progressing after treatment with 5-fluorouracil (FU), irinotecan (lrl) and oxaliplatin (oxa) [J] . C.Aschele, S.Lonardi, S.Garrè, European Journal of Cancer Supplements . 2003,第5期

机译：238吉西他滨（GEM）作为5-氟尿嘧啶（FU），伊立替康（lrl）和奥沙利铂（oxa）治疗后进展期大肠癌（CRC）患者的治疗
3. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients [J] . European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2017,第期

机译：用伊立替康/西替昔单抗的治疗序列，然后进行Folfox-4或转移性结肠直肠癌患者的反向策略，在第一线Folfiri / Bevacizumab后进展：用于研究胃肠癌期III的意大利组，随机试验比较两种治疗序列结肠直肠转移性患者
4. VDI healthcare management: Surgical oncology, management model and formalization of knowledge: Case studies CRC (colorectal cancer) [C] . Gil C.Redondo, Martinez R.Alonso, Blanco C.Esteban, Iberian Conference on Information Systems and Technologies . 2014

机译：VDI医疗保健管理：外科肿瘤学，管理模型和知识的形式化：案例研究CRC（结直肠癌）
5. Inflammation, Type 2 Diabetes, and Cancer: Identifying Biomarkers Associated with Colorectal Cancer and Type 2 Diabetes, and the Use of microRna Molecules as a Therapeutic Use for Cancer Treatment [D] . Guillen, Jenni. 2020

机译：炎症，2型糖尿病和癌症：鉴定与结肠直肠癌和2型糖尿病相关的生物标志物，以及使用MicroRNA分子作为癌症治疗的治疗用途
6. Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer [O] . D Cunningham, S Falk, D Jackson 2002

机译：伊立替康联合5-氟尿嘧啶和亚叶酸作为转移性结直肠癌的一线治疗的临床和经济效益
7. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC) [O] . J. Tabernero, A. Grothey, E. Van Cutsem, 2019

机译：Encorafenib Plus与BINIMETINIB用于BRAF V600E-突变转移性结肠直肠癌的Cetuximab：来自随机，3臂，III期研究的扩增结果与伊立替康或FOLFIRI加入uTuximab（Beacon CRC）的选择

PCN171 IDENTIFYING STRUCTURAL UNCERTAINTY IN ECONOMIC MODELS OF CANCER TREATMENTS: A CASE STUDY OF IRINOTECAN IN COLORECTAL CANCER (CRC)

著录项

相似文献

相关主题

期刊订阅